Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 million. The company expects next quarter’s revenue to be around $71.5 million, close to analysts’ estimates. Its GAAP profit of $0.68 per share was 3% above analysts’ consensus estimates.
Is now the time to buy LMAT? Find out in our full research report (it’s free for active Edge members).
LeMaitre (LMAT) Q1 CY2026 Highlights:
- Revenue: $66.55 million vs analyst estimates of $66.72 million (11.2% year-on-year growth, in line)
- EPS (GAAP): $0.68 vs analyst estimates of $0.66 (3% beat)
- Adjusted EBITDA: $22.36 million vs analyst estimates of $20.19 million (33.6% margin, 10.8% beat)
- The company reconfirmed its revenue guidance for the full year of $280 million at the midpoint
- EPS (GAAP) guidance for the full year is $3.01 at the midpoint, beating analyst estimates by 3.5%
- Operating Margin: 26.7%, up from 21.1% in the same quarter last year
- Organic Revenue rose 10% year on year (miss)
- Market Capitalization: $2.56 billion
StockStory’s Take
LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns over certain operational trends. Management credited the quarter’s results to continued strength in core product lines—especially Artegraft, which saw exceptional international growth—and disciplined pricing strategies. CEO George LeMaitre noted, “Worldwide Artegraft sales grew 36% in Q1,” while also acknowledging product and geographic expansion as central to recent performance.
Looking ahead, LeMaitre’s guidance is built on continued international rollout of Artegraft, further pricing initiatives, and operational investments to support expansion. Management highlighted upcoming launches in Canada and other regions, new product variants, and ongoing salesforce growth as key contributors to expected growth. CFO Dorian LeBlanc stated, “We are increasing our annual guidance for gross margin to 72.3%,” emphasizing the company’s focus on margin improvement and direct-to-hospital sales execution.
Key Insights from Management’s Remarks
Management emphasized that international growth, pricing discipline, and product innovation were primary contributors to the quarter’s performance, with Artegraft emerging as a central growth engine.
-
Artegraft international momentum: Artegraft’s strong global sales were driven by expanded approvals and new use cases, with European demand for longer grafts fueling growth. Management is prioritizing filings for longer versions and new geographic launches, targeting Canada in the next half-year and several Asian and South American markets in 2027.
-
Pricing strategies underpin margins: The company achieved 8% average selling price increases through both U.S. and European markets. Management discussed price floors and noted that while U.S. pricing is largely locked in, Europe still offers room for additional pricing actions—though implementation is slower due to three-year tender cycles.
-
Manufacturing and operational efficiencies: Gross margin gains were attributed not only to pricing, but also to ongoing manufacturing consolidation and lean initiatives, including automation and warehouse expansion across Europe. The company reduced direct labor headcount while increasing device output, reflecting sustained productivity improvements.
-
Mixed performance in other categories: While Artegraft and related products posted robust gains, patches—specifically XenoSure—saw only modest growth, reflecting normalization after prior supply disruptions for competitors and a more challenging prior-year comparison.
-
M&A pipeline and capital allocation: Management remains active in M&A, focusing on niche targets in open vascular and cardiac surgery, but has raised its bar for acquisitions due to confidence in organic growth. As President Dave Roberts noted, “We’re out hunting...but we’re waiting for our pitch,” signifying a disciplined approach given limited attractive targets.
Drivers of Future Performance
LeMaitre’s outlook is guided by international product launches, continued pricing actions, and operational investments, as well as monitored risks from supply chain dynamics and new market entries.
-
International expansion and new approvals: The upcoming launches of Artegraft in Canada and regulatory filings for Korea, Brazil, Vietnam, and India are expected to support further revenue growth. Management also highlighted the role of the Irish warehouse in enabling pan-European distribution, with direct entry into Poland slated for later this year.
-
Margin sustainability and operational investments: Management projects continued gross margin strength through pricing and efficiency projects, but flagged incremental investments in salesforce expansion and manufacturing transitions—such as the Billerica warehouse and Burlington RFA facility—as potential near-term cost headwinds.
-
Product development and regulatory risk: The pursuit of Quick Stick claims for Artegraft and development of longer graft sizes offer upside, but timelines for regulatory approval remain uncertain. Management acknowledged that Quick Stick approvals could take two to six years, with volume and share gains dependent on successful outcomes.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will closely watch (1) the pace of Artegraft’s international rollout and the impact of new product variants, (2) progress on regulatory filings and direct market entries, particularly in Canada and Poland, and (3) sustained margin performance amid ongoing operational investments. Developments in M&A and further efficiency initiatives could also influence LeMaitre’s growth and profitability trajectory.
LeMaitre currently trades at $104.42, down from $112 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.